Kyverna reports positive topline data from Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome

Kyverna Therapeutics, Inc.

Positive topline data from registrational Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome (SPS).
Trial KYSA-8 evaluates fully human autologous CD19 CAR T-cell therapy with CD28 co-stimulation.
Company to host conference call on Dec 15, 2025 at 8:00 AM ET to discuss results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.